

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (ORIGINAL) A method for the detection of an angiogenic disease or disorder in an individual comprising the steps of:
 - a. isolating platelets from said individual at a first time point;
 - b. analyzing said platelets for the level of at least one positive or at least one negative angiogenic regulator;
 - c. isolating platelets from said individual at a second time point, said second time point being after said first time point;
 - d. analyzing said platelets from said second time point for the level of at least one positive or at least one negative angiogenic regulator; and
 - e. comparing the levels of said angiogenic regulator from the first time point to the levels of said angiogenic regulator from said second time point, wherein an increase in the level of said at least one positive angiogenic regulator in the platelets from said second time point or a decrease in at least one negative angiogenic regulator in the platelets from said second time point is indicative of an angiogenic disease or disorder.
- 2.– 4. (CANCELLED)
5. (CURRENTLY AMENDED) The method of claim 1, ~~2, or 3~~, wherein the platelets are isolated from a blood sample.
6. (CURRENTLY AMENDED) The method of claim 1, ~~2, or 3~~, wherein the positive angiogenic regulator is selected from the group consisting of, VEGF-A (VPC), VEGF-C, bFGF, HGF, angiopoietin-1, PDGF, EGF, IGF-1, IGF BP-3, BDNF, matrix metalloproteinases (MMPs), vitronectin, fibronectin, fibrinogen, heparanase, and sphingosine-1 PO₄.
7. (CURRENTLY AMENDED) The method of claim 1, ~~2, or 3~~, wherein the negative angiogenic regulator is selected from the group consisting of, PF-4, thrombospondin- 1 & 2, NK1, NK2, NK3 fragments of HGF, TGF-beta-1, plasminogen (angiotatin), plasminogen activator inhibitor 1, alpha-2 antiplasmin and fragments thereof, alpha-2 macroglobulin, tissue inhibitors of metalloproteinases (TIMPs), beta-thromboglobulin, edostatin, tumstatin, and soluble VEGFR2.

8. (CURRENTLY AMENDED) The method of claim 1, ~~2, or 3~~, wherein the platelets are analyzed for the presence of at least one angiogenic regulator using a method selected from the group consisting of a protein array, ELISA, Western Blot, surface enhanced laser desorption ionization spectroscopy (SELDI), and Mass Spectrometry.
9. (CURRENTLY AMENDED) The method of claim 1, ~~2, or 3~~, wherein the individual has a genetic predisposition to cancer.
10. (ORIGINAL) The method of claim 9, wherein the genetic predisposition to cancer is a mutation in a tumor suppressor gene.
11. (ORIGINAL) The method of claim 10, wherein the tumor suppressor gene is selected from the group consisting of BRCA1, BRCA2, p53, p10, LKB1, MSH2, and WT1.
12. (CURRENTLY AMENDED) The method of claim 1, ~~2, or 3~~, wherein the individual has been previously treated for cancer or an angiogenic disease or disorder.
13. (CURRENTLY AMENDED) The method of claim 1, ~~2, or 3~~, wherein the individual is believed to be a healthy, disease-free individual.
14. (CURRENTLY AMENDED) The method of claim 1, ~~2, or 3~~, wherein said second time point is at least one month after said first time point.
15. (CURRENTLY AMENDED) The method of claim 1, ~~2, or 3~~, wherein said second time point is at least 2 months after said first time point.
16. (CURRENTLY AMENDED) The method of claim 1, ~~2, or 3~~, wherein said second time point is at least 6 months after said first time point.
17. (CURRENTLY AMENDED) The method of claim 1, ~~2, or 3~~, wherein said second time point is at least 10 months after said first time point.
18. (CURRENTLY AMENDED) The method of claim 1, ~~2, or 3~~, wherein said second time point is at least one year after said first time point.
19. (CURRENTLY AMENDED) The method of claim 1, ~~2, or 3~~, wherein the cancer is selected from the group consisting of gastrointestinal cancer, prostate cancer, ovarian cancer, breast cancer, head and neck cancer, lung cancer, non-small cell lung cancer, cancer of the nervous system, kidney cancer, retina cancer, skin cancer, liver cancer, pancreatic cancer, genital-urinary cancer and bladder cancer.
20. - 21(CANCELLED)
22. (CURRENTLY AMENDED) The method of claim ~~2 and 3~~ 1, wherein said angiogenic disease or disorder is selected from the group consisting of cancer, retinopathy, diabetic retinopathy, macular degeneration, restenosis, inflammatory disease, arthritis, rheumatoid arthritis, psoriasis, crohns, benign tumors, hemangiomas, neurofibromas and granulomas.

23. – 29. (CANCELLED)

30. (CURRENTLY AMENDED) The method of claim ~~28~~ 22, wherein the ~~angiogenic~~
~~disease or disorder~~ cancer is selected from the group consisting of gastrointestinal cancer,
prostate cancer, ovarian cancer, breast cancer, head and neck cancer, lung cancer, non-
small cell lung cancer, cancer of the nervous system, kidney cancer, retina cancer, skin
cancer, liver cancer, pancreatic cancer, genital-urinary cancer, bladder cancer,
retinopathy, diabetic retinopathy, macular degeneration, restenosis, inflammatory disease,
arthritis, rheumatoid arthritis, psoriasis, chrohsn, benign tumors, hemangiomas,
neurofibromas and granulomas.

31. – 34 (CANCELLED)